Pregledni rad

POST-TRANSPLANT ERYTHROCYTOSIS

ŽELJKA MUSTAPIĆ ; Klinički bolnčki centar Zagreb i Medicinski fakultet Sveučilišta u Zagrebu, Zavod za nefrologiju, arterijsku hipertenziju i dijalizu, Zagreb, Hrvatska
NIKOLINA BAŠIĆ-JUKIĆ ; Klinički bolnčki centar Zagreb i Medicinski fakultet Sveučilišta u Zagrebu, Zavod za nefrologiju, arterijsku hipertenziju i dijalizu, Zagreb, Hrvatska
VESNA LOVČIĆ ; Opća bolnica Bjelovar, Odjel za nefrologiju, Bjelovar, Hrvatska
PETAR KES ; Klinički bolnčki centar Zagreb i Medicinski fakultet Sveučilišta u Zagrebu, Zavod za nefrologiju, arterijsku hipertenziju i dijalizu, Zagreb, Hrvatska

Sažetak

Post-transplant erythrocytosis is defined as an increase in hematocrit above 55%. It occurs in 10%-15% of renal transplant recipients, most commonly from 8 to 24 months after transplantation. Twenty-five percent of patients experience spontaneous remission within 2 years, while 75% develop symptoms and signs of hyperviscosity (headache, hypertension, plethora). The etiology is multifactorial and includes erythropoietin, renin-angiotensin system (RAS) and IGF-1 as the main factors. RAS inhibition with either ACE inhibitors or angiotensin receptor blockers is efficient therapy which decreases hematocrit in 90% of patients within 2 to 6 weeks, thus decreasing the incidence of fatal complications (like pulmonary embolism and stroke).

Ključne riječi

erythrocytosis; renal transplantation; etiology; treatment

Hrčak ID:

89613

URI

https://hrcak.srce.hr/89613

Datum izdavanja:

1.3.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.334 *